Estrogen- and antiestrogen-responsiveness of HEC1A endometrial adenocarcinoma cells in culture

被引:38
作者
Castro-Rivera, E [1 ]
Safe, S [1 ]
机构
[1] Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA
关键词
D O I
10.1016/S0960-0760(97)00202-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
HEC1A endometrial cancer cells express the wild-type form of the estrogen receptor (ER) and 17 beta-estradiol (E2) induces proliferation of these cells. In contrast, tamoxifen only causes a minimal increase (<20%) in cell proliferation. In HEC1A cells transiently transfected with the C3-Luc plasmid derived from the complement C3 gene, both E2 and tamoxifen exhibited ER agonist activity and tamoxifen was also a partial antagonist for this response. The relative ER agonist/antagonist activities of E2, tamoxifen and ICI 182,780 were also investigated in HEC1A1 cells transiently transfected with two E2-responsive plasmids, pCATHD-CAT and pCKB-CAT which contain 5'-promoter inserts from the cathepsin D and creatine kinase B genes, respectively. The results showed that E2 and tamoxifen induced reporter gene activity in cells transiently transfected with both constructs. ICI 182,780 exhibited partial ER agonist activity only in cells transiently transfected with pCKB-CAT and antagonized E2-induced reporter gene activity using both the CKB- and CATHD-derived constructs. These results demonstrate that HEC1A endometrial cancer cells are E2-responsive and represent a useful cell culture model for understanding hormone/antihormone-induced endometrial cell responses. (C) 1998 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:287 / 295
页数:9
相关论文
共 57 条
  • [1] ANZAI Y, 1989, CANCER RES, V49, P2362
  • [2] ESTROGENS AND GROWTH-FACTORS INDUCE THE MESSENGER-RNA OF THE 52K-PRO-CATHEPSIN-D SECRETED BY BREAST-CANCER CELLS
    CAVAILLES, V
    AUGEREAU, P
    GARCIA, M
    ROCHEFORT, H
    [J]. NUCLEIC ACIDS RESEARCH, 1988, 16 (05) : 1903 - 1919
  • [3] POPULATION-BASED STUDY OF TAMOXIFEN THERAPY AND SUBSEQUENT OVARIAN, ENDOMETRIAL, AND BREAST CANCERS
    COOK, LS
    WEISS, NS
    SCHWARTZ, SM
    WHITE, E
    MCKNIGHT, B
    MOORE, DE
    DALING, JR
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (18) : 1359 - 1364
  • [4] Second cancers after adjuvant tamoxifen therapy for breast cancer
    Curtis, RE
    Boice, JD
    Shriner, DA
    Hankey, BF
    Fraumeni, JF
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (12) : 832 - 834
  • [5] ESTROGENIC REGULATION OF GROWTH AND POLYPEPTIDE GROWTH-FACTOR SECRETION IN HUMAN-BREAST CARCINOMA
    DICKSON, RB
    LIPPMAN, ME
    [J]. ENDOCRINE REVIEWS, 1987, 8 (01) : 29 - 43
  • [6] DICKSON RB, 1986, CANCER SURV, V5, P617
  • [7] ENDOMETRIAL CANCER IN TAMOXIFEN-TREATED BREAST-CANCER PATIENTS - FINDINGS FROM THE NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT (NSABP) B-14
    FISHER, B
    COSTANTINO, JP
    REDMOND, CK
    FISHER, ER
    WICKERHAM, DL
    CRONIN, WM
    BOWMAN, D
    COUTURE, J
    DIMITROV, NV
    EVANS, J
    FARRAR, W
    KAVANAH, M
    LICKLEY, HL
    MARGOLESE, R
    PATERSON, AHG
    ROBIDOUX, A
    SHIBATA, H
    TERZ, J
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (07): : 527 - 537
  • [8] FRIES LAG, 1995, JNCI-J NATL CANCER I, V87, P867
  • [9] Estrogen activates migration potential of endometrial cancer cells through basement membrane
    Fujimoto, J
    Hori, M
    Ichigo, S
    Morishita, S
    Tamaya, T
    [J]. TUMOR BIOLOGY, 1996, 17 (01) : 48 - 57
  • [10] GONG YW, 1992, CANCER RES, V52, P1704